AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more
AMGN (AMGN) - Net Assets
Latest net assets as of December 2025: CA$8.66 Billion CAD
Based on the latest financial reports, AMGN (AMGN) has net assets worth CA$8.66 Billion CAD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$90.59 Billion) and total liabilities (CA$81.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$8.66 Billion |
| % of Total Assets | 9.56% |
| Annual Growth Rate | 33.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.8 |
AMGN - Net Assets Trend (2022–2025)
This chart illustrates how AMGN's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AMGN (2022–2025)
The table below shows the annual net assets of AMGN from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$8.66 Billion | +47.32% |
| 2024-12-31 | CA$5.88 Billion | -5.70% |
| 2023-12-31 | CA$6.23 Billion | +70.23% |
| 2022-12-31 | CA$3.66 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to AMGN's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 351500000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$33.77 Billion | 389.99% |
| Total Equity | CA$8.66 Billion | 100.00% |
AMGN Competitors by Market Cap
The table below lists competitors of AMGN ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eicher Motors Limited
NSE:EICHERMOT
|
$10.58 Billion |
|
Tenaga Nasional Bhd
KLSE:5347
|
$10.59 Billion |
|
Computershare Limited
PINK:CMSQF
|
$10.59 Billion |
|
BorgWarner Inc
NYSE:BWA
|
$10.61 Billion |
|
WFD Unibail Rodamco NV
PINK:UNBLF
|
$10.56 Billion |
|
UDR Inc
NYSE:UDR
|
$10.55 Billion |
|
China CITIC Bank Corporation Limited
F:D7C
|
$10.55 Billion |
|
Smurfit Kappa Group Plc
PINK:SMFTF
|
$10.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AMGN's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,877,000,000 to 8,658,000,000, a change of 2,781,000,000 (47.3%).
- Net income of 7,711,000,000 contributed positively to equity growth.
- Dividend payments of 5,124,000,000 reduced retained earnings.
- Other factors increased equity by 194,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$7.71 Billion | +89.06% |
| Dividends Paid | CA$5.12 Billion | -59.18% |
| Other Changes | CA$194.00 Million | +2.24% |
| Total Change | CA$- | 47.32% |
Book Value vs Market Value Analysis
This analysis compares AMGN's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.12x to 1.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | CA$6.86 | CA$28.28 | x |
| 2023-12-31 | CA$11.64 | CA$28.28 | x |
| 2024-12-31 | CA$10.94 | CA$28.28 | x |
| 2025-12-31 | CA$16.07 | CA$28.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AMGN utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 89.06%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.98%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 10.46x
- Recent ROE (89.06%) is below the historical average (111.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 178.97% | 24.89% | 0.40x | 17.79x | CA$6.19 Billion |
| 2023 | 107.78% | 23.83% | 0.29x | 15.59x | CA$6.09 Billion |
| 2024 | 69.59% | 12.24% | 0.36x | 15.63x | CA$3.50 Billion |
| 2025 | 89.06% | 20.98% | 0.41x | 10.46x | CA$6.85 Billion |
Industry Comparison
This section compares AMGN's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.